文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

SPARC试验:前列腺癌立体定向放疗联合病灶聚焦推量初步结果

Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-10-20

SPARC试验纳入新诊断中高危前列腺癌患者,采用CyberKnife进行5次36.25 Gy的SABR,并对mpMRI可见的病灶同步推量至最高47.5 Gy。前8例患者中位随访56个月,计划依从性好,2级及以上急性泌尿和胃肠毒性均为37.5%,晚期泌尿毒性12.5%、胃肠毒性0%,所有患者维持生化缓解。

要点

  • 中高危前列腺癌SABR联合mpMRI病灶聚焦推量可行,计划依从性好。
  • 2级及以上急性泌尿和胃肠毒性均为37.5%,晚期泌尿毒性12.5%。
  • 中位随访56个月,所有患者维持生化缓解。

核心结论

  • 前列腺SABR联合病灶聚焦推量在SPARC试验首批患者中成功实施,计划方案依从性极好,毒性和疗效结果有前景。

研究设计与样本

  • SPARC试验为前瞻性试验,纳入新诊断中高危前列腺癌患者,要求mpMRI可见病灶且允许最多2个独立结节,所有患者接受雄激素剥夺治疗。
  • 患者接受CyberKnife 5次36.25 Gy的SABR,病灶同步推量至最高47.5 Gy(受危及器官约束限制)。
  • 本次对2013年7月至2015年12月入组的前8例患者进行中期安全性分析,中位随访56个月(范围50-74)。

主要发现

  • 前列腺PTV的D95中位值为36.55 Gy(范围35.87-36.99),推量体积D95中位值为46.62 Gy(范围44.85-48.25)。
  • 80项剂量约束中有10项未达到,但均为轻微剂量偏差。
  • 2级及以上急性泌尿和胃肠毒性分别为37.5%和37.5%,2级及以上晚期泌尿和胃肠毒性分别为12.5%和0%。
  • IIEF和EQ-5D全球健康评分随时间恢复,所有患者维持生化缓解。

关键数值与推荐

  • 入组标准:新诊断中高危前列腺癌,至少满足以下之一:Gleason评分4+3、T3a期、PSA>20 ng/ml。
  • mpMRI必须可见病灶,允许最多2个独立结节。
  • 处方剂量:5次36.25 Gy,病灶同步推量至最高47.5 Gy,受危及器官约束限制。
  • 毒性采用RTOG评分标准,性功能和健康相关生活质量分别采用IIEF和EQ-5D评估。

临床怎么用

  • 对于mpMRI可见病灶的中高危前列腺癌,可考虑SABR联合病灶聚焦推量,但需严格受危及器官约束限制推量剂量。
  • 治疗中应密切监测急性和晚期泌尿、胃肠毒性,并定期评估性功能和生活质量。

局限性

  • 本次分析仅纳入前8例患者,为中期间安全性分析,样本量小。
  • 随访时间有限,中位56个月,长期疗效和毒性有待进一步随访。
  • 所有患者均接受雄激素剥夺治疗,结果可能受联合治疗影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Dose escalation to dominant intraprostatic lesions (DILs) is a novel method to increase the therapeutic ratio in localised prostate cancer. The Stereotactic Prostate Augmented Radiotherapy with Cyberknife (SPARC) trial was designed to determine the feasibility of a focal boost defined with multiparametric magnetic resonance imaging (mpMRI) using stereotactic ablative body radiotherapy (SABR). MATERIALS AND METHODS: Patients were included with newly diagnosed intermediate to high risk prostate cancer with at least one of: Gleason score 4 + 3, stage T3a, or PSA > 20 ng/ml. Visible disease on mpMRI was mandatory and up to 2 separate nodules were allowed. All patients received androgen deprivation. Patients received 36.25 Gy in 5 fractions using CyberKnife® and the DIL received a simultaneous boost to a maximum of 47.5 Gy, as allowed by OAR constraints. Genitourinary (GU) and gastrointestinal (GI) toxicity was reported using the RTOG scoring criteria. International Index of Erectile Function (IIEF) and EQ-5D global health scores were regularly captured. RESULTS: An interim safety analysis was performed on the first 8 patients, recruited between July 2013 and December 2015. Median follow up was 56 months (range 50-74). Median D95 values for the prostate PTV and boost volume were 36.55 Gy (range 35.87-36.99) and 46.62 Gy (range 44.85-48.25) respectively. Of the dose constraints, 10/80 were not achieved but all were minor dose variations. Grade 2+ acute GU and GI toxicities were 37.5% respectively while grade 2+ late GU and GI toxicities were 12.5% and 0% respectively. IIEF and quality of life scores recovered over time and all patients remain in biochemical remission. CONCLUSION: The first patients have been successfully treated with prostate SABR and focal boost on the SPARC trial, with excellent adherence to the planning protocol. Toxicity and efficacy results are promising and further recruitment is underway.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nicholls L, Suh YE, Chapman E, et al. Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial. Clin Transl Radiat Oncol. 2020. PMID: 33145444. doi:10.1016/j.ctro.2020.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。